Goldberg
Law PC (http://www.Goldberglawpc.com)
announces that it is investigating claims of potential
misrepresentations by TransEnterix, Inc (“TransEnterix” or the
“Company”) (NYSE MKT: TRXC). The investigation focuses on whether the
Company and its officers violated securities laws by issuing misleading
information to investors.
If you purchased or otherwise acquired TransEnterix shares and would
like more information regarding the investigation, we advise you to
contact Michael Goldberg
or Brian Schall, of
Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA
90067, at 800-977-7401, to discuss your rights without cost to you. You
can also reach us through the firm’s website at http://www.Goldberglawpc.com,
or by email at info@goldberglawpc.com.
The investigation concerns whether the Company violated Sections 10(b)
and 20(a) of the Securities Exchange Act of 1934. Specifically, the
investigation will focus on the Company’s April 20, 2016, press release
stating that the FDA informed the Company that "SurgiBot™ System does
not meet the criteria for substantial equivalence based upon the data
and information submitted by TransEnterix in its 510(k) submission.
If you have any questions concerning your legal rights in this case,
please immediately contact Goldberg Law PC at 800-977-7401, or visit our
website at http://www.Goldberglawpc.com,
or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes
in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160422005832/en/
Copyright Business Wire 2016